Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology
Healthcare
$2.38 +85.71%
+$1.20 today
- Market cap
- $56.20M
- Beta
- 0.97
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$2.50
52W Low $0.96High $2.75
Volume 0.13M
Average 0.22M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$46.66M
FY 2025 · Annual
Investing Cash Flow
$37.80M
FY 2025 · Annual
Financing Cash Flow
$141,000.00
FY 2025 · Annual
-99.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Depreciation & Amortization | 682K | 942K | 957K | 1.09M | 1.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.16M | 2.29M | 3.34M | 7.52M | 6.13M |
| Change in Working Capital | (837K) | 866K | (799K) | (1.68M) | 3.46M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.91M | 0 | 775K | 1.63M |
| Other Working Capital | (837K) | (1.05M) | (799K) | (2.45M) | 1.83M |
| Other Non-Cash Items | 959K | 2.21M | (915K) | (2.4M) | 698K |
| Operating Cash Flow | (23.25M) | (39.6M) | (46.86M) | (60.84M) | (46.66M) |
| Capital Expenditures | (2.03M) | (1.07M) | (633K) | (2.54M) | (546K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.49M) | (42.6M) | (160.12M) | (208.47M) | (174.9M) |
| Sales of Investments | 20.24M | 59.8M | 122.5M | 184.9M | 213.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (59.29M) | 16.13M | (38.26M) | (26.1M) | 37.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 126K | 0 | 93M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 208K | 0 | (1.77M) | (3.18M) | 0 |
| Financing Cash Flow | 105.53M | 126K | 97.9M | 89.82M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 22.99M | (23.34M) | 12.78M | 2.88M | (8.72M) |
| Free Cash Flow | (25.28M) | (40.66M) | (47.49M) | (63.38M) | (47.21M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$58.2M
+ D&A$1.3M
+ Stock-Based Comp$6.1M
+ Deferred Tax$0
+ Working Capital$3.5M
+ Other Non-Cash$698.0K
= Operating Cash Flow-$46.7M
- Capex-$546.0K
= Free Cash Flow-$47.2M
Analysis
FY2025 free cash flow is -$47.2M. FCF conversion is 81.1% of net income. Operating cash flow was -$46.7M, with capex of -$546.0K. The largest bridge item is Stock-Based Comp at $6.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| EFFECT | EFFECT filing | Nov 3, 2026 | |
| 424B3 | 424B3 filing | Nov 3, 2026 |
Does BOLD generate free cash flow?
Boundless Bio, Inc. (BOLD) generated -$47.21M of free cash flow in fiscal 2025.
How much operating cash flow does BOLD produce?
Operating cash flow was -$46.66M, before capital expenditures of $546,000.00.
Continue the stock analysis
Jump to another research area for this company.